Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND CODEINE PHOSPHATE vs CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors (VDR) and suppresses keratinocyte proliferation while inducing differentiation. Betamethasone dipropionate is a potent corticosteroid that binds to glucocorticoid receptors, inhibiting pro-inflammatory mediators and reducing inflammation, pruritus, and vasodilation.
Mild to moderate pain,Pain accompanied by fever
FDA: topical treatment of plaque psoriasis in patients 12 years and older,Off-label: scalp psoriasis, nail psoriasis, parapsoriasis
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
Apply to affected areas once daily; maximum weekly dose should not exceed 100 g (calcipotriene 0.005% and betamethasone dipropionate 0.064% as combination ointment or foam).
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Calcipotriene: not applicable due to minimal systemic exposure. Betamethasone dipropionate: terminal half-life of betamethasone after topical application is approximately 5-6 hours.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Calcipotriene: hepatic metabolism via CYP24A1 and other enzymes; betamethasone dipropionate: mainly hepatic metabolism via CYP3A4 to various inactive metabolites.
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Calcipotriene: negligible systemic absorption; absorbed fraction undergoes hepatic metabolism and is excreted in feces (approx. 70%) and urine (approx. 20%). Betamethasone dipropionate: absorbed dose metabolized in liver, metabolites excreted primarily in urine (60-70%) and feces (20-30%).
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
Calcipotriene: >90% bound to plasma proteins (albumin). Betamethasone dipropionate: >90% bound to albumin.
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Calcipotriene: not clinically relevant due to low systemic absorption. Betamethasone dipropionate: Vd of betamethasone is approximately 1.4 L/kg, indicating wide distribution.
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
Topical: systemic bioavailability of calcipotriene is <1% of applied dose; betamethasone dipropionate is <10% of applied dose through intact skin, but increases with inflamed skin.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
Safety and efficacy in pediatric patients (age <12 years) have not been established. For patients 12–17 years, dosing is same as adult; maximum weekly dose not to exceed 60 g per week.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
No specific dose adjustment required; however, caution due to potential for increased skin atrophy, impaired renal/hepatic function, and concurrent medications. Use minimal effective amount.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
No FDA boxed warning.
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
May cause hypercalcemia due to calcipotriene absorption, especially when applied to large areas or occluded skin,Risk of hypothalamic-pituitary-adrenal (HPA) axis suppression from betamethasone, particularly with prolonged use, high potency, or large surface area,Local adverse reactions: skin atrophy, striae, telangiectasias, folliculitis, perioral dermatitis, allergic contact dermatitis,Not for use on face, groin, or axillae due to increased systemic absorption and skin atrophy risk,Caution in patients with renal impairment or hepatic impairment due to metabolic and excretory pathways,Do not use with occlusive dressings unless directed,May mask signs of infection and suppress immune response
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
Hypersensitivity to calcipotriene, betamethasone dipropionate, or any components,Patients with known hypercalcemia or vitamin D toxicity,Active infections of skin (viral, fungal, bacterial) at treatment site,Concurrent use of other vitamin D analogues topically,Severe renal or hepatic impairment (relative)
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
No clinically significant food-drug interactions. However, maintain adequate calcium and vitamin D intake as part of a balanced diet, but avoid excessive calcium supplementation due to potential hypercalcemia risk with extensive use.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
FDA Pregnancy Category C. Calcipotriene: No adequate human studies; animal studies show no teratogenicity at topical doses. Bethamethasone dipropionate: Corticosteroids can cause cleft palate, intrauterine growth restriction, and adrenal suppression in animal studies; human risk with topical use is low due to minimal systemic absorption. Avoid large areas or prolonged use in pregnancy. First trimester: theoretical risk but limited data. Second/third trimesters: low risk if used sparingly.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
Not known if excreted in human milk. Calcipotriene is likely excreted due to low molecular weight; betamethasone may appear in milk. M/P ratio not available. Use caution; apply smallest amount to smallest area, avoid breast area. Consider benefits vs risks.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
No formal dose adjustment guidelines. Use minimum effective dose for shortest duration. Avoid occlusion, extensive areas, or prolonged treatment. Monitor for local and systemic adverse effects.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
Avoid use on face, groin, axillae, or in intertriginous areas due to increased risk of corticosteroid side effects. Apply only to affected plaques; limit total weekly dose to ≤100 g or 60 m L to minimize risk of HPA axis suppression. Discontinue if skin atrophy, telangiectasias, or striae develop. Monitor for hypercalcemia in patients with extensive plaque psoriasis due to calcipotriene absorption. For patients with moderate-to-severe plaque psoriasis, consider sequential or rotational therapy to minimize long-term corticosteroid exposure.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
Apply a thin layer to psoriatic plaques once daily for up to 4 weeks as directed.,Do not use on the face, armpits, groin, or areas with skin folds.,Wash hands after application unless treating hands.,Avoid contact with eyes and mucous membranes.,Do not use occlusive dressings (e.g., bandages, wraps) over the treated area.,Inform your doctor if you develop severe skin irritation, signs of skin infection, or if psoriasis worsens.,Do not use more than the prescribed amount or for longer than recommended.
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND CODEINE PHOSPHATE vs CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE, answered by our medical review team.
ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE is a Vitamin D Analog that works by Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors (VDR) and suppresses keratinocyte proliferation while inducing differentiation. Betamethasone dipropionate is a potent corticosteroid that binds to glucocorticoid receptors, inhibiting pro-inflammatory mediators and reducing inflammation, pruritus, and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND CODEINE PHOSPHATE and CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. The standard adult dose of CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE is: Apply to affected areas once daily; maximum weekly dose should not exceed 100 g (calcipotriene 0.005% and betamethasone dipropionate 0.064% as combination ointment or foam).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND CODEINE PHOSPHATE and CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE is classified as Category C. FDA Pregnancy Category C. Calcipotriene: No adequate human studies; animal studies show no teratogenicity at topical doses. Bethamethasone dipropionate: Corticosteroids can cause c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.